Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma

✍ Scribed by Tim Eisen; Uwe Trefzer; Anne Hamilton; Peter Hersey; Michael Millward; Robert D. Knight; Jarl U. Jungnelius; John Glaspy

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 259 KB
• Volume: 116
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.24686